WHAT IS DNDi DOING TO ADDRESS UNMET TREATMENT NEEDS?
Short term: better use of existing treatments through new formulations
- Paediatric strength of benznidazole: first treatment designed specifically for children
Medium term: development of new treatments through therapeutic switching
and combination therapy
- Azoles: clinical development of a well-known compounds already developed against fungal infections for use as Chagas disease monotherapy and/or in combination with existing drugs
Long term: new drugs, and improved research & treatment capacity across
region
- Nitroimidazoles: a well-known class of anti-infective compounds
- New drugs developed from promising compounds identified in discovery activities (such as GSK library of pyridones and cysteine protease inhibitors) and progressed through Chagas lead optimisation consortium
- A multi-country, multi-partner Chagas clinical research platform in preparation
By 2014, DNDi aims to deliver from its Chagas-specific portfolio:
- 1 new paediatric strength available
- 1 new drug registered
- A robust pipeline
|
